© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
In February 2022, the FDA granted accelerated approval to pacritinib for intermediate or high-risk primary or secondary myelofibrosis with severe thrombocytopenia.
March 4th 2022
March 2nd 2022
March 1st 2022
Ruben Mesa, MD, spoke about the approval of pacritinib and its importance for the treatment of myelofibrosis.